Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors

BACKGROUND: Although epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) have been the standard treatment for advanced EGFR‐mutant adenocarcinoma, the effects of upfront EGFR‐TKI use in unresectable stage III EGFR‐mutant adenocarcinoma remain unexplored. Here, we conducted a retr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Sheng‐Yuan, Lai, Ching‐Han, Chen, Chian‐Wei, Yang, Szu‐Chun, Chang, Chao‐Chun, Lin, Chia‐Ying, Yen, Yi‐Ting, Tseng, Yau‐Lin, Su, Po‐Lan, Lin, Chien‐Chung, Su, Wu‐Chou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758433/
https://www.ncbi.nlm.nih.gov/pubmed/34799993
http://dx.doi.org/10.1111/1759-7714.14237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758433/
https://www.ncbi.nlm.nih.gov/pubmed/34799993
http://dx.doi.org/10.1111/1759-7714.14237

Ejemplares similares